Monday, June 24, 2019

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer Reinhard et al. The Lancet. Oncology 2018 19(10) 1315-1327

Main|Search|PHGKB



Last Posted: Jun-24-2019 11AM

Last Posted: Jun 24, 2019


No comments:

Post a Comment